Cardima, Inc. (OTCBB: CADM) Cardima ispleased to announce that Dr. Jaswinder Gill of Guy's and St. Thomas'sHospital will be giving a presentation titled, "Left and Right LinearAtrial Ablation Using a Novel System" at the upcoming first annual EuropeAF Symposium. Cardima is a sponsor of this new and important meeting thatwill be headed by Co-Directors Dr. Riccardo Cappato (Milan, Italy) and Dr.Wyn Davies (London, UK). Leading electrophysiologists from around theworld will be attending.
Dr. Gill will be speaking on his experience using the Cardima EP AblationSystem at Guy's and St. Thomas's Hospital to treat patients with bothparoxysmal and persistent atrial fibrillation. Dr. Gill is leading anindependent study using the Cardima System and will present data todemonstrate that it can be used safely and effectively to replicate the CoxMaze procedure for the treatment of AF. To date, Guy's and St. Thomas'sHospital has treated over 110 AF patients using the Cardima EP AblationSystem.
Cardima's CEO, Robert Cheney, commented: "Cardima feels it is important tobe a sponsor of this new and important conference in the UK where ourdistributor, Dot Medical, is in the process of establishing commercialCardima programs and training cardiac centers to use the Cardima EPAblation System. We are especially pleased that the conference directorshave selected Dr. Gill to give a talk. Dr. Gill will have an opportunityto present his extensive experience using our products to effectively treatAF at his hospital to leading electrophysiologists from around the world."
Earlier this year Dr. Gill had his abstract selected for presentation atthe Fourth Annual Congress of the European Cardiac Arrhythmia Society(ECAS) in Marseille, France. This abstract was subsequently accepted forpublication in the Journal of Interventional Cardiac Electrophysiology,vol. 22:1, 2008.
About Cardima
Cardima, Inc. has developed the PATHFINDER®, TRACER® and VUEPORT®Series of diagnostic catheters, the NAVIPORT® Series of guidingcatheters, the REVELATION® Series of ablation catheters, the SurgicalAblation System with its series of ablation probes, and the INTELLITEMP®Energy Management Device Series for RF (radiofrequency) energy management.These devices are CE marked and/or received U.S. FDA 510(k) clearance. TheREVELATION Series of ablation catheters with the INTELLITEMP EP EnergyManagement Device was developed and marketed for the treatment of atrialfibrillation (AF) with CE mark approval in Europe; it is not yetcommercially available in the U.S.
For more information, please visit the Company's website atwww.cardima.com.
Forward-Looking Statements
Except for the historical information contained herein, the mattersdiscussed in this press release are forward-looking statements that involverisks and uncertainties that could cause actual results to differmaterially from those expressed in or implied by such forward-lookingstatements, including but not limited to using the Cardima System todemonstrate that it can be used safely and effectively to replicate the CoxMaze procedure for the treatment of AF. Potential risks and uncertaintiesinclude, but are not limited to: the uncertainties associated with theprospects for FDA approval of any new devices; the prospect for any futureclinical trials or regulatory activities; the risk that the Company willnot be able to raise additional capital in the immediate term as needed tocontinue operations and the risk that we will be unable to secure FDAapproval for the EP ablation applications in the USA and CE mark for theSurgical Ablation probe series with Sheath. Additional risks anduncertainties are set forth in the Company's Annual Report on Form 10-KSBfor the year ended December 31, 2007, the Company's Quarterly Report onForm 10-QSB and in the Company's other filings with the Securities andExchange Commission. The Company undertakes no obligation to publiclyrelease the result of any revisions to these forward-looking statementsthat may be made to reflect events or circumstances after the date hereof,or to reflect the occurrence of unanticipated events or changes in theCompany's plans or expectations.
Contact:
Tony Shum
Cardima, Inc.
(510) 354-0300
http://www.Cardima.com
